Thalidomide's tightly controlled "comeback"

Cleveland Clinic Journal of Medicine

Volumn 66, Issue 3, 1999, Pages 136-138

  Calabrese, Leonard H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; THALIDOMIDE;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APHTHOUS ULCER; ARTICLE; AUTOIMMUNE DISEASE; BIRTH DEFECT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISCOID LUPUS ERYTHEMATOSUS; DRUG COST; ERYTHEMA NODOSUM LEPROSUM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; MYCOBACTERIOSIS; NEUROPATHY; PHOCOMELIA; RHEUMATOID ARTHRITIS; SOLID TUMOR; SOMNOLENCE; TREATMENT INDICATION; WASTING SYNDROME;

AUTOIMMUNE DISEASES; HIV INFECTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEPROSTATIC AGENTS; THALIDOMIDE;

EID: 0032949040     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.66.3.136     Document Type: Article

References (16)

1. Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exper Med 1991; 173:699-703.
2. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J Exper Med 1993; 177:1675-1680.
3. Faure M, Thivolet J, Gaucherand M. Inhibition of PMN leukocyte chemotaxis by thalidomide. Arch Dermatol Res 1980; 269:275-280.
4. McHugh SM, Rifkin IR, Deighton J, et al. The immunosuppressive drug thalidomide induces T helper cell type T (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exper Immunol 1995; 99:160-167.
5. Gad SM, Shannon EJ, Krotoski WA, et al. Thalidomide induces imbalances in T-lymphocyte sub-populations in the circulating blood of healthy males. Lepr Rev 1985; 56:35-39.
6. D'Amato RJ, Loughnan MS, Flynne E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91:4082-4085.
7. Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med 1997; 336:1487-1493.
8. Kaplan G, Schambelan M, Gottlieb M, et al. Thalidomide reverses cachexia in HIV-wasting syndrome. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, 1998, abstract no. 476.
9. Sharpstone D, Rowbottom A, Nelson M, Gazzard B. The treatment of microsporidial diarrhoea with thalidomide. AIDS 1995; 9:658-659.
10. Quinones F, Sierra-Madero J, Calva-Mercado JJ, Ruiz-Palacios GM. Thalidomide in patients with HIV infection and chronic diarrhea: Double-blind, placebo-controlled clinical trial. 4th Conference on Retroviruses and Opportunistic Infections. Washington, 1997, abstract no. 682.
11. Sharpstone D, Rowbottom A, Francis N, et al. Thalidomide: A novel therapy for microsporidiosis. Gastroenterology 1997; 112:1823-1829.
12. Gutierrez-Rodriguez O. Thalidomide: A promising new treatment for rheumatoid arthritis. Arthritis Rheum 1984; 27:1118-1121.
13. Scoville CD. Open trial using methotrexate and thalidomide in the treatment of rheumatoid arthritis (abstract). Arth Rheum 1998; 41(9Suppl):S60.
14. Lo JS, Berg RE, Tomecki KJ. Treatment of discoid lupus erythematosus. Int J Dermatol 1989; 28:497-507.
15. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of Behçet's syndrome: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128:443-450.
16. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992; 326:1055-1058.